SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity

被引:156
作者
Pan, XH [1 ]
Ikeda, SR [1 ]
Lewis, DL [1 ]
机构
[1] Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
关键词
D O I
10.1124/mol.54.6.1064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CB1 cannabinoid receptor antagonist SR 141716A abolished the inhibition of Ca2+ currents by the agonist WIN 55,212-2. However, SR 141716A alone increased Ca2+ currents, with an EC50 of 32 nM, in neurons that had been microinjected with CBI cRNA. For an antagonist to elicit an effect, some receptors must be tonically active. Evidence for tonically active CBI receptors was seen as enhanced tonic inhibition of Ca2+ currents. Preincubation with anandamide failed to enhance the effect of SR 141716A, indicating that anandamide did not cause receptor activity. Under Ca2+-free conditions designed to block the Ca2+-dependent formation of anandamide and sn-2-arachidonylglycerol, SR 141716A again increased the Ca2+ current. The Ca2+ current was tonically inhibited in neurons expressing the mutant K192A receptor, which has no affinity for anandamide, demonstrating that this receptor is also tonically active. SR 141716A had no effect on the Ca2+ current in these neurons, but SR 141716A could still antagonize the effect of WIN 55,212-2. Thus, the K192 site is critical for the inverse agonist activity of SR 141716A. SR 141716A appeared to become a neutral antagonist at the K192A mutant receptor. Native cannabinoid receptors were studied in male rat major pelvic ganglion neurons, where it was found that WIN 55,212-2 inhibited and SR 141716A increased Ca2+ currents. Taken together, our results demonstrate that a population of native and cloned CBI cannabinoid receptors can exist in a tonically active state that can be reversed by SR 141716A, which acts as an inverse agonist.
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 40 条
[21]   AM630 is an inverse agonist at the human cannabinoid CB1 receptor [J].
Landsman, RS ;
Makriyannis, A ;
Deng, HF ;
Consroe, P ;
Roeske, WR ;
Yamamura, HI .
LIFE SCIENCES, 1998, 62 (09) :PL109-PL113
[22]   Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors [J].
MacLennan, SJ ;
Reynen, PH ;
Kwan, J ;
Bonhaus, DW .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (04) :619-622
[23]   STRUCTURE OF A CANNABINOID RECEPTOR AND FUNCTIONAL EXPRESSION OF THE CLONED CDNA [J].
MATSUDA, LA ;
LOLAIT, SJ ;
BROWNSTEIN, MJ ;
YOUNG, AC ;
BONNER, TI .
NATURE, 1990, 346 (6284) :561-564
[24]   IDENTIFICATION OF AN ENDOGENOUS 2-MONOGLYCERIDE, PRESENT IN CANINE GUT, THAT BINDS TO CANNABINOID RECEPTORS [J].
MECHOULAM, R ;
BENSHABAT, S ;
HANUS, L ;
LIGUMSKY, M ;
KAMINSKI, NE ;
SCHATZ, AR ;
GOPHER, A ;
ALMOG, S ;
MARTIN, BR ;
COMPTON, DR ;
PERTWEE, RG ;
GRIFFIN, G ;
BAYEWITCH, M ;
BARG, J ;
VOGEL, Z .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (01) :83-90
[25]  
PACHECO M, 1991, J PHARMACOL EXP THER, V257, P170
[26]  
Pan XH, 1996, MOL PHARMACOL, V49, P707
[27]   PHARMACOLOGICAL CHARACTERIZATION OF 3 NOVEL CANNABINOID RECEPTOR AGONISTS IN THE MOUSE ISOLATED VAS-DEFERENS [J].
PERTWEE, RG ;
GRIFFIN, G ;
LAINTON, JAH ;
HUFFMAN, JW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 284 (03) :241-247
[28]   Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder [J].
Pertwee, RG ;
Fernando, SR .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (08) :2053-2058
[29]   A PRELIMINARY INVESTIGATION OF THE MECHANISMS UNDERLYING CANNABINOID TOLERANCE IN THE MOUSE VAS-DEFERENS [J].
PERTWEE, RG ;
GRIFFIN, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 272 (01) :67-72
[30]   INHIBITORY EFFECTS OF CERTAIN ENANTIOMERIC CANNABINOIDS IN THE MOUSE VAS-DEFERENS AND THE MYENTERIC PLEXUS PREPARATION OF GUINEA-PIG SMALL-INTESTINE [J].
PERTWEE, RG ;
STEVENSON, LA ;
ELRICK, DB ;
MECHOULAM, R ;
CORBETT, AD .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 105 (04) :980-984